Tetragenetics

AbCellera grew out of the idea that single-cell microfluidics and next-generation technologies can radically change how we discover drugs. We are motivated by the feeling that our days are being well spent. Before leading AbCellera, Carl cofounded Precision Nanosystems, a global leader in technologies, solutions, and services for the development of non-viral delivery of genomic medicines, including mRNA vaccines and therapeutics. Andrew became AbCellera’s CFO in 2019 after spending nearly 4 years on the company’s Board of Directors from 2016. Prior to joining AbCellera, Neil was the Global Marketing Lead for Amgen’s General Medicine early portfolio, which included responsibility for developing the integrated strategy for Amgen’s non-oncology therapeutic areas and leading commercial strategy for over 10 biologics, as well as several high profile corporate initiatives. Before joining AbCellera, Murray was a Business Development Manager at Harvard University’s Office of Technology Development. Prior to joining AbCellera, Adam was most recently Senior Director, Biologics Lead Antibody Discovery at Teva Pharmaceuticals. Before joining AbCellera, Janet was Managing Director of Student Development and Services at the University of British Columbia.